EU/3/19/2240

Table of contents

About

On 9 January 2020, orphan designation EU/3/19/2240 was granted by the European Commission to BIT Pharma GmbH, Austria, for nicardipine for the treatment of non-traumatic subarachnoid haemorrhage.

Key facts

Active substance
nicardipine
Disease / condition
Treatment of non-traumatic subarachnoid haemorrhage
Date of first decision
09/01/2020
Outcome
Positive
EU designation number
EU/3/19/2240

Sponsor's contact details

Bit Pharma GmbH
Leonhardstrasse 109
8010 Graz
Austria
Tel. +43 6643 972384
E-mail: tiziana.adage@bit-pharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating